|
1
|
Lemesle G, Delhaye C, Bonello L, de
Labriolle A, Waksman R and Pichard A: Stent thrombosis in 2008:
definition, predictors, prognosis and treatment. Arch Cardiovasc
Dis. 101:769–777. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kurz DJ and Eberli FR: Medical therapy of
coronary artery disease after percutaneous intervention. Curr Opin
Pharmacol. 13:287–293. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wallentin L, Becker RC, Budaj A, et al:
Ticagrelor versus clopidogrel in patients with acute coronary
syndromes. N Eng J Med. 361:1045–1057. 2009. View Article : Google Scholar
|
|
4
|
Amsterdam EA, Wenger NK, Brindis RG, Casey
DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF,
Kontos MC, et al: American Association for Clinical Chemistry:
22014 AHA/ACC Guideline for the Management of Patients with
Non-ST-Elevation Acute Coronary Syndromes: a report of the American
College of Cardiology/American Heart Association Task Force on
Practice Guidelines. J Am Coll Cardiol. 64:e139–e228. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kubica AI, Kozinski M, Grzesk G, Fabiszak
T, Navarese EP and Goch A: Genetic determinants of platelet
response to clopidogrel. J Thromb Thrombolysis. 32:459–466. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Husted S and van Giezen JJ: Ticagrelor:
the first reversibly binding oral P2Y12 receptor antagonist.
Cardiovasc Ther. 27:259–274. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gurbel PA, Bliden KP, Butler K, Tantry US,
Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, et
al: Randomized double-blind assessment of the ONSET and OFFSET of
the antiplatelet effects of ticagrelor versus clopidogrel in
patients with stable coronary artery disease: The ONSET/OFFSET
study. Circulation. 120:2577–2585. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Juneja S, Gupta K and Kaushal S:
Ticagrelor: An emerging oral antiplatelet agent. J Pharmacol
Pharmacother. 4:78–80. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wallentin L, Becker RC, Budaj A, Cannon
CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, et
al: PLATO Investigators: Ticagrelor versus clopidogrel in patients
with acute coronary syndromes. N Engl J Med. 361:1045–1057. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gaglia MA Jr and Waksman R: Overview of
the 2010 Food and Drug Administration Cardiovascular and Renal
Drugs Advisory Committee meeting regarding ticagrelor. Circulation.
123:451–456. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
DiNicolantonio JJ, D'Ascenzo F, Tomek A,
Chatterjee S, Niazi AK and Biondi-Zoccai G: Clopidogrel is safer
than ticagrelor in regard to bleeds: a closer look at the PLATO
trial. Int J Cardiol. 168:1739–1744. 2013. View Article : Google Scholar : PubMed/NCBI
|
